Abstract

**Objectives:** To assess the association between plasma homocysteine (Hcy), blood pressure (BP) and poor outcome at hospital discharge among acute ischemic stroke patients, and if high Hcy increases the risk of poor outcome based on high BP status in a northern Chinese population.

**Methods:** Between June 1, 2009 and May 31, 2013, a total of 3695 acute ischemic stroke patients were recruited from three hospitals in northern Chinese cities. Demographic characteristics, lifestyle risk factors, medical history, and other clinical characteristics were recorded for all subjects. Poor outcome was defined as a discharge modified Rankin Scale (mRS) score ≥3 or death. The association between homocysteine concentration, admission blood pressure, and risk of poor outcome following acute ischemic stroke was analyzed by using multivariate non-conditional logistic regression models.

**Results:** Compared with those in the lowest quartile of Hcy concentration in a multivariate-adjusted model, those in the highest quartile of Hcy concentration had increased risk of poor outcome after acute ischemic stroke, (OR = 1.33, 95%CI, 1.19–1.74). Compared with non-high BP with hHcy, high BP with nhHcy, and high BP with hHcy to poor outcome were 1.14 (0.85–1.53), 1.37 (1.03–1.84) and 1.70 (1.29–2.34), respectively.

**Conclusion:** The present study suggested that high plasma Hcy and blood pressure were independent risk factors for prognosis of acute ischemic stroke, and high BP may further increase the risk of poor outcome among patients with high blood pressure. Additionally, the results indicate that high Hcy with high BP may cause increased susceptibility to poor outcome among acute ischemic stroke patients in a northern Chinese population.

Introduction

Stroke is the second most common cause of death and the leading cause of serious, long-term disability worldwide [1]. The burden of stroke is high and growing in economically developing countries [2]. In China, stroke accounts for 21.6% of total mortality in males and 20.8% of total mortality in females [3]. The total incidence of stroke is projected to increase considerably over the next two decades [4].

Homocysteine (Hcy), a sulphur-containing amino acid, was hypothesized to affect atherosclerotic processes as early as 1969 [5]. Since that time, numerous epidemiological studies have demonstrated a positive association between Hcy level and stroke incidence [6–9]. A meta-analysis of prospective studies supports the possibility that the association between plasma Hcy and stroke may be causal: a 5 μmol/l Hcy elevation causes a 59% increase in stroke risk, while a 3 μmol/l Hcy reduction leads to a 24% decrease in stroke risk [9]. Previous research has found that elevated Hcy is associated with poor outcome among acute
ischemic stroke patients [10–12], but inconsistent results still exist [13–16]. A study in a Korean population, after a 12-month follow-up, shows that plasma Hcy levels have no value as predictors of functional outcome [13].

Epidemiological studies have documented that high blood pressure (BP) is the most important modifiable risk factor for the incidence of stroke [17,18]. In China, hypertensive patients usually have high homocysteine (hHcy) concentration levels and the proportion is about 75%. A large sample of epidemiological research demonstrated that the incidence of cardiovascular events in hypertensive patients with high Hcy is about 5 times higher than in patients with hypertension alone, and about 25–30 times higher than in those without hypertension [19]. And a nationwide study showed elevated total plasma homocysteine and hypertension had a multiplicative effect on the odds of prevalent stroke [20]. Few studies to date have examined the cumulative effect of high BP at admission and Hcy concentration on poor outcome among stroke patients, especially in a northern Chinese population.

Thus, we sought to assess the relationship between high plasma homocysteine, blood pressure and poor discharge outcome among acute ischemic stroke patients. We also examined if hHcy may increase the risk of poor outcome based on high BP status in a northern Chinese population.

Methods

Study participants

From June 1, 2009 to May 31, 2013, we recruited adult patients with a clinical diagnosis of acute ischemic stroke from three hospitals in northern cities in China (the People’s Hospital of XingAnMeng in Inner Mongolia, the Center Hospital of FuXin in LiaoNing province and ChengDe Medical College Affiliated Hospital in HeBei province). All participants were recruited within 7 days of symptom onset. Exclusion criteria were: (1) lack of plasma homocysteine concentration measurement; (2) lack of blood pressure data; (3) presence of illnesses including renal and kidney disease, malignancy, autoimmune disease, and hypothyroidism; and (4) inability to comply with a magnetic resonance examination.

Thus, we sought to assess the relationship between high plasma homocysteine, blood pressure and poor discharge outcome among acute ischemic stroke patients. We also examined if hHcy may increase the risk of poor outcome based on high BP status in a northern Chinese population.

Table 1. Baseline characteristics of acute ischemic stroke patients with good outcome or poor outcome.

|                     | Good outcome (mRS = 0,1,2) | Poor outcome (mRS = 3,4,5 or dead) | P-value |
|---------------------|---------------------------|-----------------------------------|---------|
| N                   | 3105                      | 590                               |         |
| Age                 | 62.14±11.27               | 63.77±12.27                       | 0.006   |
| Male no,%           | 2009,64.70                | 372,63.05                         | 0.442   |
| Days hospitalized (days) | 13.21±7.71               | 16.94±12.00                       | <0.001  |
| Onset to hospital admission time (hours) | 48(18,106)               | 48(10,96)                         | 0.001   |
| Smoker no,%         | 1184,38.13                | 226,38.31                         | 0.937   |
| Drinker no,%        | 980,31.56                 | 170,28.81                         | 0.186   |
| Admission SBP (mmHg) | 145.61±27.66              | 148.55±23.57                      | 0.007   |
| Admission DBP (mmHg) | 88.33±13.15               | 89.36±13.11                       | 0.081   |
| High BP no,%        | 1593,51.30                | 360,61.02                         | <0.001  |
| History of Hypertension no,% | 2054,66.15     | 398,67.46                        | 0.538   |
| History of Hyperglycemia no,% | 615,19.81     | 115,19.49                        | 0.860   |
| History of coronary heart disease no,% | 406,13.08 | 94,15.93                        | 0.063   |
| History of atrial fibrillation, no,% | 50,1.61     | 16,2.71                          | 0.064   |
| Glucose (mmol/l)    | 6.75±3.63                 | 6.63±3.09                         | 0.435   |
| Hyperglycemia no,%  | 1285,41.38                | 244,41.36                         | 0.989   |
| TG (mmol/l)         | 1.79±1.39                 | 1.53±1.62                         | <0.001  |
| TC (mmol/l)         | 4.84±1.79                 | 4.60±1.19                         | <0.001  |
| LDL cholesterol (mmol/l) | 3.14±0.87          | 3.02±0.97                         | 0.007   |
| HDL cholesterol (mmol/l) | 1.12±0.30          | 1.10±0.28                         | 0.135   |
| Dyslipidemia no,%   | 1766,56.88                | 305,51.69                         | 0.020   |
| Hcy (umol/l)        | 20.40±15.31               | 21.78±17.23                       | 0.071   |

All values are expressed with mean±standard deviation unless otherwise noted. SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure; TG, triglycerides; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Hcy, homocysteine.

doi:10.1371/journal.pone.0107498.t001

Ethics Statement

This study was approved by the Soochow University Ethics Committee. Written informed consent was obtained from all study participants.

Data Collection

Demographic characteristics, lifestyle risk factors, medical history, clinical laboratory tests and imaging data (CT and MRI) were recorded within the first 24 h after admission to hospital by a face to face interview with patients or their family members (if patients were not able to communicate). All information was obtained using a standard questionnaire administered by trained staff. Cigarette smoking was defined as having smoked at least 1 cigarette per day for 1 year or more. The amount and type of alcohol consumed during the past year were collected. Alcohol consumption was defined as consuming one or more alcoholic drink per day during the last year. Blood pressure (BP) was measured in the first 72 h (one measurement every 8 h) after hospital admission and plasma homocysteine concentration was measured within 7 days of symptom onset.
admission while the participants were in the supine position using a standard mercury sphygmomanometer according to a standard protocol. The first and fifth Korotkoff sounds were recorded as systolic (SBP) and diastolic BP (DBP), respectively. High admission BP was defined as SBP $\geq 140$ mmHg and/or DBP $\geq 90$ mmHg. History of hypertension was defined that patients have hypertension prior to admission to hospital, according to the question “have you received a diagnosis of hypertension from any doctor or hospital before this onset of stroke”, or use of antihypertensive medication, or SBP $\geq 140$ mmHg and/or DBP $\geq 90$ mmHg.

Hcy, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides were analyzed on a Beckman Synchron CX5 Delta Clinical System (Beckman Coulter, Inc., Fullerton, California, USA) using commercial reagents [21]. Plasma glucose was measured by a modified hexokinase enzymatic method [22]. The criterion of dyslipidemia was as follows: total cholesterol $\geq 6.22$ mmol/l or triglyceride $\geq 2.26$ mmol/l or LDL cholesterol $\geq 4.14$ mmol/l or HDL cholesterol $< 1.04$ mmol/l. Hyperglycemia was defined as fasting plasma glucose $\geq 6.1$ mmol/l. High Hcy (hHcy) was defined as Hcy $> 15$ umol/l, and nhHcy was Hcy $\leq 15$ umol/l [23,24].

Acute ischemic stroke was confirmed by imaging (CT scan or MRI) according to the acute ischemic stroke diagnosis and treatment guidelines in China. Study outcome was evaluated using the modified Rankin Scale (mRS) obtained at hospital discharge, and poor outcome was defined as a mRS score $\geq 3$ or death.

## Statistical analysis

Statistical analysis was conducted using SAS statistical software (version 9.1, Cary, North Carolina, USA). Patients were divided into two groups according to study outcome: mRS $\leq 3$ and mRS $> 3$ or death. According to blood pressure and concentration level of Hcy, participants were divided into four groups: non-high BP with non-hHcy (nhHcy), non-high BP with hHcy, high BP with nhHcy, and high BP with hHcy. Baseline characteristics of continuous variables were compared in 2 or 4 subgroups using Student’s t-test or ANOVA. Categorical variables were expressed as percentage and compared between groups using Chi-square test. Plasma Hcy concentration was divided into four quartiles ($< 11.9$ umol/l, 11.9-16.1 umol/l, 16.1-23.3 umol/l, $\geq 23.3$ umol/l; $< 11.9$ umol/l is the lowest quartile and $\geq 23.3$ umol/l is the highest quartile). Univariate and multivariate non-conditional logistic regression models were used to assess the association between Hcy, blood pressure and discharge outcome among acute ischemic stroke patients. Odd ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the risk of poor outcome after adjusting for important confounding factors. Multivariable interaction models were used to evaluate the interaction of Hcy and blood pressure with poor outcome among acute ischemic stroke patients. All P values were 2-tailed, and a significance level of 0.05 was used.

## Results

A total of 3695 patients (2381 males and 1314 females) were included in this study. The mean age of the participants was 62.40 $\pm$ 11.45 years. Table 1 shows baseline characteristics at admission in patients with good outcome (mRS $= 0, 1, 2$) and poor outcome (mRS $= 3, 4, 5$ or dead). Age, high BP percentage, hospitalized days and SBP were higher in the poor outcome group.
whereas onset to hospital admission time, TG, TC, LDL cholesterol and proportion of dyslipidemia were higher in the good outcome group. There were no significant differences in Hcy and other variables between the two groups.

Table 2 shows that there was a significant association between Hcy concentration and risk of poor outcome. Compared with patients in the lowest quartile of Hcy concentration, those in the highest quartile faced an increased risk of poor outcome (OR = 1.29, \( P < 0.05 \)). After adjustment for age, gender, days hospitalized, onset to hospital admission time, smoking, drinking, history of hypertension, history of hyperglycemia, history of coronary heart disease, history of atrial fibrillation, high BP, hyperglycemia, and dyslipidemia, those in the highest quartile still had an increased risk of poor outcome (OR = 1.33, \( P < 0.05 \)). The dose-response relationship between Hcy concentration and risk of poor outcome remained significant after adjustment for other covariates (p-value for trend = 0.027).

As shown in Table 3, ORs of poor outcome were significant in patients with an onset to hospital admission time >96 hours, those with a history of hypertension, and those with dyslipidemia. The ORs (95% CIs) were 1.32 (1.04–1.68), 1.17 (1.02–1.33) and 1.23 (1.06–1.44), respectively.

We also analyzed the independent effect of admission blood pressure on poor outcome after acute ischemic stroke. The multivariable-adjusted OR (95% CI) of poor outcome was 1.44 (1.19–1.74). Table 4 summarizes the baseline characteristics of participants according to blood pressure and level of Hcy.

### Table 3. Sub-group analysis on the association between plasma homocysteine and poor outcome among acute ischemic stroke patients.

| Subgroup                          | NO. of participants | Poor outcome n,% | OR(95%CI) |
|-----------------------------------|---------------------|------------------|-----------|
|                                  | nhHcy   | hHcy   | nhHcy   | hHcy   |          |
| **Age, y**                        |         |        |         |        |          |
| ≤62                               | 62      | 967    | 957     | 131    | 13.6     | 1.06(0.93–1.22) |
| >62                               | 685     | 1086   | 112     | 16.4   | 0.05     | 1.11(0.94–1.30) |
| **Gender**                        |         |        |         |        |          |
| Male                              | 846     | 1535   | 122     | 14.4   | 0.05     | 1.10(0.94–1.29) |
| Female                            | 806     | 508    | 121     | 15.0   | 0.05     | 1.13(0.99–1.28) |
| **Days hospitalized, d**          |         |        |         |        |          |
| ≤13                               | 862     | 1115   | 95      | 11.0   | 0.05     | 1.13(0.96–1.34) |
| >13                               | 790     | 928    | 148     | 18.7   | 0.05     | 1.10(0.96–1.26) |
| **Onset to hospital admission time, h** |         |        |         |        |          |
| ≤24                               | 719     | 888    | 113     | 15.7   | 0.05     | 1.12(0.96–1.30) |
| 24–96                             | 467     | 543    | 82      | 17.6   | 0.05     | 0.95(0.80–1.12) |
| >96                               | 466     | 612    | 48      | 10.3   | 0.05     | 1.32(1.04–1.68) |
| **Smoker**                        |         |        |         |        |          |
| No                                | 1137    | 1148   | 169     | 14.9   | 0.05     | 1.09(0.96–1.22) |
| Yes                               | 515     | 895    | 74      | 14.4   | 0.05     | 1.14(0.93–1.39) |
| **Drinker**                       |         |        |         |        |          |
| No                                | 1226    | 1319   | 191     | 15.6   | 0.05     | 1.07(0.96–1.20) |
| Yes                               | 426     | 724    | 52      | 12.2   | 0.05     | 1.25(0.98–1.59) |
| **High BP**                       |         |        |         |        |          |
| No                                | 788     | 954    | 98      | 12.4   | 0.05     | 1.07(0.91–1.26) |
| Yes                               | 864     | 1089   | 145     | 16.8   | 0.05     | 1.21(0.98–1.29) |
| **History of Hypertension**       |         |        |         |        |          |
| No                                | 585     | 658    | 91      | 15.6   | 0.05     | 0.99(0.84–1.17) |
| Yes                               | 1067    | 1385   | 152     | 14.2   | 0.05     | 1.17(1.02–1.33) |
| **Hyperglycemia**                 |         |        |         |        |          |
| No                                | 885     | 1281   | 127     | 14.4   | 0.05     | 1.14(0.98–1.32) |
| Yes                               | 767     | 762    | 116     | 15.1   | 0.05     | 1.07(0.92–1.23) |
| **Dyslipidemia**                  |         |        |         |        |          |
| No                                | 716     | 908    | 128     | 17.9   | 0.05     | 0.98(0.85–1.13) |
| Yes                               | 936     | 1135   | 115     | 12.3   | 0.05     | 1.23(1.06–1.44) |

nhHcy was defined as Hcy >15 umol/l and nhHcy was Hcy ≤15 umol/l.

doi:10.1371/journal.pone.0107498.t003
Homocysteine, Blood Pressure and Outcome of Acute Ischemic Stroke

Table 4. Baseline characteristics of participants according to blood pressure and level of Hcy.

|                                | Non-high BP nhHcy | Non-high BP hHcy | High BP nhHcy | High BP hHcy | P-value |
|--------------------------------|-------------------|------------------|---------------|--------------|---------|
| N                              | 1332              | 410              | 1449          | 504          |         |
| Age                            | 62.4±11.4         | 63.4±12.3        | 62.3±11.2     | 62.2±11.6    | 0.323   |
| Male no,%                      | 806,60.51         | 342,83.41        | 848,58.52     | 385,76.39    | <0.001  |
| Days hospitalized (days)       | 13.5±8.2          | 12.8±6.2         | 14.4±9.8      | 13.7±7.6     | 0.001   |
| Onset to hospital admission time (hours) | 48(20,128) | 56(24,120) | 48(12,120) | 48(10,124) | <0.001 |
| Smoker no,%                    | 477,35.81         | 209,50.98        | 476,32.85     | 248,49.21    | <0.001  |
| Drinker no,%                   | 369,27.70         | 160,39.02        | 418,28.85     | 203,40.28    | <0.001  |
| Admission SBP (mmHg)           | 128.2±11.5        | 127.9±10.6       | 161.9±29.4    | 162.7±18.2   | <0.001  |
| Admission DBP (mmHg)           | 80.0±8.00         | 79.9±8.08        | 95.5±11.9     | 97.7±12.9    | <0.001  |
| History of Hypertension no,%   | 701,52.63         | 236,57.56        | 1133,78.19    | 382,75.79    | <0.001  |
| History of Hyperglycemia no,%  | 287,21.55         | 51,12.44         | 322,22.22     | 70,13.89     | <0.001  |
| History of coronary heart disease no,% | 190,14.26 | 55,13.41 | 207,14.29 | 48,9.52 | 0.041  |
| History of atrial fibrillation no,% | 27,2.03   | 12,2.93          | 25,1.73       | 2,0.40       | 0.029   |
| Glucose (mmol/l)               | 6.69±4.21         | 6.48±4.33        | 6.90±2.88     | 6.52±2.48    | 0.058   |
| Hypertension no,%              | 514,38.59         | 141,34.39        | 673,46.45     | 201,39.88    | <0.001  |
| Tg (mmol/l)                    | 1.75±1.37         | 1.63±1.11        | 1.82±1.66     | 1.61±1.00    | 0.010   |
| Tc (mmol/l)                    | 4.75±1.16         | 4.62±1.06        | 4.87±1.83     | 4.89±2.70    | 0.021   |
| LDL cholesterol (mmol/l)       | 3.09±0.86         | 3.06±0.86        | 3.15±0.90     | 3.16±0.93    | 0.147   |
| HDL cholesterol (mmol/l)       | 1.11±0.28         | 1.06±0.25        | 1.12±0.31     | 1.12±0.32    | 0.007   |
| Dyslipidemia no,%              | 733,55.03         | 235,57.32        | 828,57.14     | 275,54.56    | 0.576   |

All values are expressed with mean±standard deviation unless otherwise noted. SBP, systolic blood pressure; DBP, diastolic blood pressure; Tg, triglycerides; Tc, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Hcy, homocysteine.

doi:10.1371/journal.pone.0107498.t004

and HDL cholesterol, were significantly different among the 4 groups. Namely, smoking, drinking, history of hyperglycemia, history of coronary heart disease, hyperglycemia, and TG were lower in those with hHcy in either high BP group. Hospitalized days, admission SBP, DBP, history of hypertension, diabetes mellitus percentage, TC, LDL cholesterol, and HDL cholesterol were higher in those with hHcy or nhHcy and high BP.

As shown in table 5, compared to those with non-high BP and nhHcy, those with high BP in the nhHcy and hHcy groups were at a significantly higher risk of poor outcome compared to those with non-high BP and nhHcy. Participants with high BP and hHcy were at the highest risk in this population. To the best of our knowledge, this is the first multi-center study conducted to assess the cumulative effect of high admission BP and Hcy concentration on poor discharge outcome following acute ischemia stroke in three northern cities of China. Compared with previous studies in which Hcy and blood pressure were each shown separately to predict prognosis of stroke [12,13,26], the novelty of our study lies in its combination of these two factors to form a new variable which tests the cumulative effect on the risk of poor outcome.

Several epidemiological studies indicated that elevated Hcy concentration is an important risk factor for short-term and long-term poor outcome following acute ischemic stroke [11–13,27]. A prospective study by Tu et al. suggested that Hcy is an independent predictor of short-term outcome and mortality after acute ischemic stroke: the ORs (95% CIs) are 1.24 (1.10–1.39) and 1.14 (1.03–1.27), respectively [10]. Naess et al.’s cohort study indicated that there is an association between Hcy level and subsequent mortality in young adults in the years of following an ischemic stroke, even adjusting for traditional risk factors [11]. Meanwhile, Pniewski et al. assessed the influence of Hcy level on subsequent mortality in young adults in the years of following an ischemic stroke, even adjusting for traditional risk factors [11]. These conclusions above were shown separately to predict prognosis of stroke [12,13,26], the novelty of our study lies in its combination of these two factors to form a new variable which tests the cumulative effect on the risk of poor outcome.

Discussion

In this study, we found that there was a positive and significant association between plasma Hcy concentration and poor discharge outcome among acute ischemic stroke patients. Additionally, the results indicated that blood pressure was an independent risk factor for poor outcome among acute ischemic stroke in this study. Meanwhile, those with high BP and nhHcy or with high BP and hHcy were at a significantly higher risk of poor outcome compared to those with non-high BP and nhHcy. Participants with high BP and hHcy were at the highest risk in this population. To the best of our knowledge, this is the first multi-center study conducted to assess the cumulative effect of high admission BP and Hcy concentration on poor discharge outcome following acute ischemia stroke in three northern cities of China. Compared with previous studies in which Hcy and blood pressure were each shown separately to predict prognosis of stroke [12,13,26], the novelty of our study lies in its combination of these two factors to form a new variable which tests the cumulative effect on the risk of poor outcome.

Several epidemiological studies indicated that elevated Hcy concentration is an important risk factor for short-term and long-term poor outcome following acute ischemic stroke [11–13,27]. A prospective study by Tu et al. suggested that Hcy is an independent predictor of short-term outcome and mortality after acute ischemic stroke: the ORs (95% CIs) are 1.24 (1.10–1.39) and 1.14 (1.03–1.27), respectively [10]. Naess et al.’s cohort study indicated that there is an association between Hcy level and subsequent mortality in young adults in the years of following an ischemic stroke, even adjusting for traditional risk factors [11]. Meanwhile, Pniewski et al. assessed the influence of Hcy level on the prognosis of stroke at onset and demonstrated that mild hyperhomocysteinemia (over 15 μmol/l) could increase the risk of poor recovery for stroke [27]. These conclusions above were consistent with ours.

Some experimental studies indicate that Hcy may cause vascular inflammation and oxidative stress, damage endothelial cells, inhibit endothelium dependent relaxation, and enhance thrombogenicity [28–30]. Both minor genetic abnormalities and nutritional deficiencies of B vitamins, such as folic acid, involved in
metabolism of methionine could lead to increased Hcy concentration. Wang et al.’s meta-analysis indicated that folic supplementation significantly reduced the risk of stroke in primary prevention by 18% (RR 0.82, 95% CI 0.68–1.00; P = 0.045) [31].

Increased BP in the acute stage of ischemic stroke may be associated with poor functional outcome because there is augmentation of cerebral edema, hemorrhagic transformation, or stroke recurrence [26,32,33]. The International Stroke Trial (IST) demonstrated both high blood pressure and low blood pressure were independent prognostic factors for poor outcome [34]. Our study indicated high BP was an independent risk factor for poor discharge outcome of acute ischemic stroke. Homocysteine may elevate blood pressure by causing arterial stiffness due to impaired vascular endothelial integrity and/or by reducing the efficiency of vasodilation [35]. The National Health and Nutrition Examination Survey (NHANES), a nationally representative cross-sectional sample of the US population, showed that individuals with a combination of elevated total Hcy and hypertension were substantially more likely to have prevalent stroke compared to individuals without either condition (OR 12.02, 95%CI 6.36–22.73 for men and OR 17.34, 95%CI 10.49–28.64 for women), and the survey also indicated that elevated total Hcy and hypertension had a multiplicative effect on the odds of prevalent stroke [20]. However, the cumulative effect of high BP and Hcy concentration on the risk of poor outcome is still unclear. Our data indicated that high BP with Hcy resulted in a higher risk for poor discharge outcome in this population, with a 1.70-fold increased risk compared with non-high BP with normal Hcy. Elevated Hcy with high BP seems to increase the risk of poor outcome among acute ischemic stroke patients. The coexistence of elevated Hcy and high BP is a notable issue and suggests that lowering Hcy concentration may improve the prognosis of patients with acute ischemic stroke beyond antihypertensive treatment alone.

In the present study, the mean age of the participants was 62.40 ± 11.45 years, which is lower than that in western countries [36,37]. The mean age of people with stroke is increasing worldwide, possibly due to an ageing population; however, a worrisome trend of increasing stroke incidence in young adults has been reported for some countries, especially in low-income developing nations [36]. This is largely attributable to the worldwide epidemic of hypertension and the increasing prevalence of smoking and other cardiovascular risk factors in young adults. Therefore, prevention is considered an effective strategy for both primary and secondary prevention of stroke. An overall healthy lifestyle, which includes not smoking, following a well-balanced diet, exercising regularly, drinking moderately, and controlling weight, may be effective in lowering blood pressure and other risk factors.

The potential limitations of this paper merit consideration. Firstly, blood pressure and plasma Hcy concentration were recorded only once at baseline, and we have no data on possible changes in blood pressure and Hcy concentration during the follow-up. Future studies should examine the association between blood pressure and Hcy concentration changes and prognosis of acute ischemic stroke. Secondly, all participants were recruited upon hospital admission and within 7 days of symptom onset, and due to this possible delay of up to 7 days since symptom onset, some patients’ Hcy concentration and blood pressure at admission may not accurately reflect the levels of Hcy and blood pressure at stroke onset. In addition, the follow-up period of our study is relatively short, which prevented an evaluation of the long-term effects of plasma Hcy on acute ischemic stroke outcomes.

In conclusion, our study suggested that high Hcy and blood pressure were independent risk factors for prognosis of acute ischemic stroke. The data indicated that high BP with elevated Hcy resulted in a higher risk for poor discharge outcome compared with non-high BP with normal Hcy. The coexistence of elevated Hcy and high BP is a notable issue and suggests that lowering Hcy concentration may improve the prognosis of patients with acute ischemic stroke beyond antihypertensive treatment alone.
ischemic stroke, and high Hcy may further increase the risk of poor outcome among patients with high blood pressure. Additionally, the results indicated that high Hcy with high BP may cause increased susceptibility to poor outcome among acute ischemic stroke patients in a northern Chinese population.

Acknowledgments

We are deeply appreciative of the participants in the study, and would like to thank Xinganmeng People’s Hospital, Fuxin Center Hospital, and Affiliated Hospital of Chengde Medical University for their support and assistance.

Author Contributions

Conceived and designed the experiments: CZ MZ WT. Performed the experiments: CZ MZ WT. Analyzed the data: CZ LL WT. Contributed reagents/materials/analysis tools: LL CL LZ. Wrote the paper: CZ LL WS.

References

1. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, et al. (2004) The global stroke initiative. The Lancet Neurology 3: 391–393.
2. Yusuf S, Reddy S, Oumpuu S, Anand S (2001) Global burden of cardiovascular disease part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 104: 2055–2094.
3. He J, Gu D, Wu X, Reynolds K, Duan X, et al. (2005) Major causes of death among men and women in China. New England Journal of Medicine 353: 1124–1134.
4. Meairs S, Wahlgren N, Direagu I, Lindvall O, Rothwell P, et al. (2006) Stroke research priorities for the next decade—a representative view of the European scientific community. Cerebrovascular Diseases 22: 73–82.
5. McCully KS (1960) Vascular pathology of homocystinuria: implications for the pathogenesis of arteriosclerosis. The American journal of pathology 56: 1129–1140.
6. Khan U, Crossley C, Kalra L, Rudd A, Wolfe CD, et al. (2008) Homocysteine and its relationship to stroke subtypes in a UK Black population the South London ethnicity and stroke study. Stroke 39: 2943–2949.
7. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, et al. (1999) C-reactive protein and homocysteine in 45 prospective cohorts. Journal of the neurological sciences 26: 310–318.
8. Woolf CD, Khan U, Crossley C, Kalra L, Rudd A, et al. (2008) Homocysteine and risk of cardiovascular disease among postmenopausal women. Jama 281: 1817–1821.
9. Io H, Moriyama Y, Saito S, Kinamara S, Tanigawa T, et al. (2004) Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 109: 2766–2772.
10. Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ: British Medical Journal 325: 1302.
11. Tu WJ, Zhao SJ, Liu TG, Yang DG, Chen H (2013) Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurological research 35: 912–921.
12. Naess H, Nyland H, Idicula T, Waje-Andreassen U (2013) C-reactive Protein in 45 prospective cohorts. Journal of the neurological sciences 26: 310–318.
13. Wang X, Qin X, Demirtas H, Li J, Mao G, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. The Lancet 369: 1876–1880.
14. Bonita R, Beaglehole R (1988) Recovery of motor function after stroke. Stroke 19: 1497–1500.
15. Stead L, Gilmore R, Vehula K, Weaver A, Decker W, et al. (2006) Impact of acute blood pressure variability on ischemic stroke outcome. Neurology 66: 1878–1881.
16. Perini F, Galloni E, Bolgan I, Bader G, Ruffini R, et al. (2005) Elevated plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. Jama 277: 1775–1781.
17. Toffoli G, Markovic D, Orbiagl L (2001) Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals a nationwide study. Journal of the neurological sciences 290: 153–157.
18. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clinical chemistry 20: 470–475.
19. Floyd R, Burren J, Snydhe P, Alberti K (1976) Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glyceral, and 3-hydroxybutyrate. Clinical chemistry 24: 1724–1729.
20. Refsum H, Smith AD, Ueland PM, Eriksen E, Clarke R, et al. (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. Clinical chemistry 50: 3–32.
21. Refsum H, Fiskerstrand T, Guttormsen A, Ueland P (1997) Assessment of homocysteine status. Journal of inherited metabolic disease 20: 286–294.
22. Refsum H, Smith AD, Ueland PM, Eriksen E, Clarke R, et al. (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. Clinical chemistry 50: 3–32.
23. Refsum H, Smith AD, Ueland PM, Eriksen E, Clarke R, et al. (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. Clinical chemistry 50: 3–32.
24. Refsum H, Smith AD, Ueland PM, Eriksen E, Clarke R, et al. (2004) Facts and recommendations about total homocysteine determinations: an expert opinion. Clinical chemistry 50: 3–32.
25. Bonita R, Beaglehole R (1988) Recovery of motor function after stroke. Stroke 19: 1497–1500.
26. Stead L, Gilmore R, Vehula K, Weaver A, Decker W, et al. (2006) Impact of acute blood pressure variability on ischemic stroke outcome. Neurology 66: 1878–1881.
27. Piwowski JA, Chodakowska-Zabrowska M, Wozniak R, Sfeir K, Stafiej A (2002) Plasma homocysteine level and the course of ischemic stroke. Acta neurobiologiae experimentalis 62: 127–130.
28. Faraci FM, Lentz SR (2004) Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke 35: 345–347.
29. Toffler GH, D Agostino RB, Jacques PF, Bostom AG, Wilson PW, et al. (2002) Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. THROMBOSIS AND HAEMOSTASIS-STUTTGART- 88: 799–804.
30. Zhang C, Gai Y, Adachi MT, Ohashi S, Aso T, et al. (2001) Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. Journal of Biological Chemistry 276: 35867–35874.
31. Wang X, Qin X, Demirtas H, Li J, Mao G, et al. (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. The Lancet 369: 1876–1880.
32. Tuttolomondo A, Di Sciaicca R, Ri Raimondo D, Pedro C, La Placa S, et al. (2011) Effects of clinical and laboratory variables and of pretreatment with cardiovascular drugs in acute ischaemic stroke: A retrospective chart review from the GIFA study. International journal of cardiology 151: 318–322.
33. Alvarez FJ, Segura T, Castellanos M, Leira R, Blanco M, et al. (2004) Cerebral hemodynamic reserve and early neurologic deterioration in acute ischemic stroke. Journal of Cerebral Blood Flow & Metabolism 24: 1267–1271.
34. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercoc PA (2002) Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 33: 1315–1320.
35. Wang H, Yoshinii M, Liu K, Tsai-JC, Perella MA, et al. (1997) Inhibition of growth and p21 ras mutylation in vascular endothelial cells by homocysteine but not cysteine. Journal of Biological Chemistry 272: 25380–25385.
36. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, et al. (2013) Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. The Lancet 383: 215–229.
37. Wang Y, Rudd AG, Wolfe CD (2013) Age and Ethnic Disparities in Incidence of Stroke Over Time The South London Stroke Register. Stroke 44: 3298–3304.